The global estrogen blockers market is estimated to be valued at US$ 15.02 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Estrogen blockers, also known as antiestrogens, are used primarily to treat breast cancers that depend on the hormone estrogen to grow. They work by blocking the action of estrogen in the breast tissues. There are different types of estrogen blocking drugs available in the market including selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs) and aromatase inhibitors. SERMs like tamoxifen help prevent breast cancer recurrence and reduce the risk of developing breast cancer in high-risk women. Aromatase inhibitors like anastrozole help stop the body from making estrogens post-menopause. These drugs are usually prescribed as adjuvant therapy after primary treatment like surgery to lower the chances of cancer recurrence.
Market key trends:
One of the key trends in the estrogen blockers market is the increasing adoption of newer generation drugs like SERDs. Some of the recently approved SERDs include elacestrant and fulvestrant which are more effective than previous generation drugs. Elacestrant was approved by the FDA in 2022 for the treatment of advanced or metastatic breast cancer. Its approval has created significant buzz in the medical community owing to its improved tolerability and efficacy profile compared to tamoxifen. Similarly, fulvestrant is now being prescribed as both adjuvant and metastatic settings. The approval of newer drugs with better safety profiles is expected to boost the growth of estrogen blockers market during the forecast period.
Porter’s Analysis
Threat of new entrants: The presence of stringent regulations by regulatory authorities such as FDA for new market entrants pose threat of new entrants in estrogen blockers market.
Bargaining power of buyers: Large presence of generic players strengthens the bargaining power of buyers in estrogen blockers market.
Bargaining power of suppliers: Established key players dominating the estrogen blockers market exercise strong bargaining power over suppliers.
Threat of new substitutes: Poor substitutability of prescription estrogen blockers limits the threat of new substitutes in estrogen blockers market.
Competitive rivalry: Strong competition exists among key established players operating in estrogen blockers market.
Key Takeaways
Global Estrogen Blockers Market Size is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing prevalence of breast cancer and rising awareness regarding estrogen blockers.
Regional analysis: North America is currently the largest as well as the fastest growing regional market for estrogen blockers, owing to increasing adoption of estrogen blockers and rising breast cancer incidence rates in the region. Europe is also expected to showcase substantial growth in the estrogen blockers market during the forecast period.
Key players: Key players operating in the estrogen blockers market are Pfizer Inc., Novartis AG, AstraZeneca PLC, Eli Lilly and Company, Merck & Co., Inc., Bristol Myers Squibb Company, Johnson & Johnson, Sanofi S.A., AbbVie Inc., and GlaxoSmithKline plc. Pfizer Inc. and AstraZeneca PLC hold significant share in global estrogen blockers market.
Read More- https://www.ukwebwire.com/estrogen-blockers-market-demand-and-future-prospects/
Breast cancer is cancer that forms in the cells of the breasts.After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.
Breast cancer can occur in both men and women, but it's far more common in womenhttps://www.egypttales.com/2021/10/health-breast-cancer.html
